Deutsche Bank lowered the firm’s price target on 10x Genomics to $55 from $60 and keeps a Buy rating on the shares. The firm’s survey across U.S. academic and clinical research laboratories suggests a softening of the academic and government end market in Q1. It dropped the price target to reflect lower revenue estimates. Spending is softening across major categories with diagnostics and consumables categories more buoyant than instrument and capex-sensitive spend, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target lowered to $45 from $55 at Barclays
- Cathie Wood’s ARK Investment bought 138K shares of 10x Genomics today
- Cathie Wood’s ARK Investment bought 241K shares of 10x Genomics today
- 10x Genomics begins commercial shipments of Chromium GEM-X products
- Cathie Wood’s ARK Investment bought 157K shares of 10x Genomics today